미국의 동물 신경변성질환 진단 시장 : 시장 규모, 점유율, 동향 분석 - 진단 검사별, 동물 유형별, 제품 유형별, 적응증별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Growth & Trends:

The U.S. veterinary neurodegenerative disease diagnostics market size is expected to reach USD 158.44 million by 2030, registering a CAGR of 7.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are growing research initiatives, the rising prevalence of neurodegenerative diseases, and support initiatives. The increasing prevalence of neurodegenerative diseases in animals is fueling rapid growth in the veterinary diagnostics sector in the U.S. Conditions like Canine Cognitive Dysfunction (CCD) and Feline Cognitive Dysfunction (FCD) are becoming more widely recognized, with evidence suggesting that nearly 73% of senior dogs and 50% of senior cats exhibit signs of cognitive decline. This heightened awareness among pet owners and veterinarians has driven demand for early and accurate diagnostic tools.

Technological innovations are propelling this sector forward. AI-enhanced imaging techniques now offer more precise interpretation of X-rays, ultrasounds, and MRIs, enabling the earlier detection of neurodegenerative diseases. Meanwhile, advanced molecular diagnostics-including PCR-based assays and next-generation sequencing-provide more accurate identification of disease markers, reflecting a broader trend toward precision medicine.

Research has also evolved significantly. Specific genetic markers once considered promising for neurodegenerative disease diagnosis have been dismissed based on newer studies, underscoring the importance of adaptable diagnostic technologies that can keep pace with shifting scientific insights. Regulatory frameworks, such as those used in bovine spongiform encephalopathy (BSE) surveillance, demonstrate the crucial role of government oversight in disease control. These programs highlight how comprehensive monitoring and robust diagnostics are vital for maintaining animal and human health.

Beyond surveillance, progress in biomarker discovery, imaging technologies, and neurobehavioral testing continues to transform the diagnostic landscape. These advancements support earlier intervention and better disease management, driving the sector toward continuous innovation. Public awareness campaigns and advocacy efforts have also played a pivotal role, boosting investment in research and development. This surge of interest in diagnostic testing reflects a shared priority-across both veterinary and human medicine-to address neurodegenerative diseases more effectively.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Highlights:

• Based on product, consumables, reagents, and kits segment held the largest revenue share in 2024, and is expected to grow at the fastest CAGR over the forecast period. This dominance can be attributed to these products being essential for routine testing, offering cost-effective, convenient, and standardized solutions for veterinarians. These products are frequently used in genetic screening, biomarker assays, and immunoassays and are key tools for diagnosing conditions like canine cognitive dysfunction.
• Based on diagnostic tests, the imaging segment held the largest market share of 45.6% in 2024. This segment consists of imaging diagnostic tests such as MRI and CT scans, whose dominance can be attributed to their ability to provide detailed, high-resolution images of the brain, which aid in detecting subtle structural changes. They help differentiate between overlapping clinical signs and are non-invasive, making them safe for repeated use.
• Based on animal type, the companion animal segment dominated the U.S. veterinary neurodegenerative disease diagnostics industry in 2024 and is also expected to grow at the fastest CAGR over the forecast period. This segment, which includes animals such as canines, felines, equines, etc., is mainly driven by rising pet ownership and increased awareness of neurodegenerative conditions like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction.
• Based on indication, the cognitive dysfunction segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. In the U.S., these diagnostic tests are most commonly conducted for cognitive dysfunction syndrome (CDS) primarily because it is highly prevalent among aging companion animals, especially dogs and cats, constituting the largest segment of pet ownership.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Research Initiatives
    • 3.2.1.2. Rising Prevalence of Neurodegenerative Diseases
    • 3.2.1.3. Support Initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardized regulations
    • 3.2.2.2. Lack of awareness in developing economies
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Pet Ownership Demographics
  • 3.3.6. Estimated Animal Population by key countries, key species, 2024

Chapter 4. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal type Movement Analysis
• 4.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by animal type, 2018 to 2030 (USD Million)
• 4.4. Livestock
  • 4.4.1. Livestock Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Sheep
    • 4.4.2.1. Sheep Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Cattle
    • 4.4.3.1. Cattle Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Companion
  • 4.5.1. Companion Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Canine
    • 4.5.2.1. Canine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Feline
    • 4.5.3.1. Feline Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Equine
    • 4.5.4.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Movement Analysis
• 5.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Diagnostic Tests, 2018 to 2030 (USD Million)
• 5.4. Imaging
  • 5.4.1. Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. MRI (Magnetic Resonance Imaging)
    • 5.4.2.1. MRI (Magnetic Resonance Imaging) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. CT (Computed Tomography)
    • 5.4.3.1. CT (Computed Tomography) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biomarker Diagnostic Tests
  • 5.5.1. Biomarker Diagnostic Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. CSF (Cerebrospinal Fluid) biomarkers
    • 5.5.2.1. CSF (Cerebrospinal Fluid) biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Blood-based biomarkers
    • 5.5.3.1. Blood-based biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Movement Analysis
• 6.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
  • 6.3.1. Consumables, Reagents & Kits
    • 6.3.1.1. Consumables, Reagents & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Equipment & Instruments
    • 6.3.2.1. Equipment & Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication, Movement Analysis
• 7.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 7.3.1. Cognitive Dysfunction
    • 7.3.1.1. Cognitive Dysfunction Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Cerebellar Abiotrophy
    • 7.3.2.1. Cerebellar Abiotrophy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Spongiform Encephalopathies
    • 7.3.3.1. Spongiform Encephalopathies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Others
    • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Movement Analysis
• 8.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.3.1. Veterinary Hospitals and Clinics
    • 8.3.1.1. Veterinary Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. Veterinary Diagnostic Laboratories
    • 8.3.2.1. Veterinary Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Others
    • 8.3.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heat Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis Services LLC.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Vrac .
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Life Diagnostics.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. ACUVET BIOTECH
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Merck & Co., Inc.
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. IDEXX Laboratories, Inc.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. MI:RNA Diagnostics Ltd.
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Mercodia AB
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Antech Diagnostics, Inc.
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Avacta Animal Health Limited
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Product launch
  • 9.4.4. Others
• 9.5. List of other key players